نتایج جستجو برای: i 125

تعداد نتایج: 1065598  

Journal: :The Journal of clinical investigation 1969
M I Surks H L Schwartz J H Oppenheimer

The formation of tissue iodoproteins during the peripheral metabolism of the thyroid hormones was examined by determining the concentration of nonethanol-extractable (125)I (NE(125)I) in various tissues after the intravenous injection of 3,5,3'-triiodo-L-thyronine (T3-(125)I) and L-thyroxine-(125)I (T4-(125)I) in groups of rats with iodide-blocked thyroid glands. 3 days after T3-(125)I and 7 da...

ayvand Taherparvar Zaynab Fardi

Introduction: Brachytherapy is one type of internal radiation therapy where radiation sources, which are usually encapsulated, are placed as close as possible to the tumor site or inside the patient's body. In this technique, it is important to determine dose distribution around the brachytherapy capsule to create optimal treatment plant. In this way, dosimetric parameters are...

Journal: :Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2003
Naoto Shikano Keiichi Kawai Leo Garcia Flores Ryuichi Nishii Nobuo Kubota Nobuyoshi Ishikawa Akiko Kubodera

UNLABELLED We evaluated the use of radiolabeled 4-iodo-L-meta-tyrosine as an amino acid transport marker. The pharmacologic features of this compound, particularly the biodistribution and excretion, were examined by conducting in vivo and in vitro studies using 4-(125)I-iodo-L-meta-tyrosine (4-(125)I-mTyr). Results obtained for L-(14)C-Tyr and 3-(125)I-iodo-alpha-methyl-L-tyrosine ((125)I-IMT) ...

ژورنال: سنجش و ایمنی پرتو 2019

Brachytherapy is one type of internal radiation therapy where radiation sources, which are usually encapsulated are placed as close as possible to the tumor site inside the patient's body. In this technique, it is important to determine dose distribution around the brachytherapy capsule. Hereby, in this paper, dosimetric parameters of I-125 brachytherapy source model 6711 are estimated accordin...

Journal: :Nuclear medicine and biology 2010
Naoto Shikano Takashi Kotani Syuichi Nakajima Masato Ogura Shinya Nakazawa Jun-ichi Sagara Masato Kobayashi Takeshi Baba Naoto Yamaguchi Nobuo Kubota Keiichi Kawai

INTRODUCTION High expression of the system L amino acid transporter has been observed in clinically important tissues including tumors and the blood-brain barrier. We examined amino acid transport system L selectivity of (14)C(U)-L-tyrosine ((14)C-Tyr), (125)I-4-iodo-L-meta-tyrosine (4-(125)I-mTyr), (125)I-6-iodo-L-meta-tyrosine (6-(125)I-mTyr), (125)I-3-iodo-α-methyl-L-tyrosine ((125)I-IMT) an...

2017
Agnieszka Morgenroth Andreas T.J. Vogg Bernd Neumaier Felix M. Mottaghy Boris D. Zlatopolskiy

Cyclooxygenase-2 (COX-2) is an important biomarker in several tumors. Available imaging probes display relatively low tumor to background ratios (smaller than 2:1). We evaluated newly developed indomethacin (Ind) derivatives for in vivo molecular imaging of COX-2 expressing carcinoma. Radioiodinated Ind derivatives Ind-NH-(CH2)4-NH-3-[I-125]I-Bz ([I-125]5), Ind-NH-(CH2)4-NH-5-[I-124/125]I-Nic (...

Journal: :The Journal of pharmacology and experimental therapeutics 2000
L T Krebs J M Hanesworth M F Sardinia R C Speth J W Wright J W Harding

This study demonstrates that a novel angiotensin I analog, angiotensinogen 3-11(Lys(11)), possesses a high affinity for angiotensin-converting enzyme (ACE), which is substantially greater than the endogenous substrates. This assessment is based on data derived from a variety of techniques. First, the binding characteristics of (125)I-angiotensinogen 3-11(Lys(11)) were examined. Equilibrium satu...

Journal: :The Journal of pharmacology and experimental therapeutics 2001
F M Dautzenberg G Py-Lang J Higelin C Fischer M B Wright G Huber

The binding characteristics of corticotropin-releasing factor (CRF) type 1 (CRF(1)) and type 2 (CRF(2)) receptors from human (hCRF(1) and hCRF(2alpha)) and Xenopus (xCRF(1) and xCRF(2)) were compared using four different (125)I-labeled CRF analogs, the agonists (125)I-CRF and (125)I-sauvagine, and the antagonists (125)I-astressin ((125)I-AST) and (125)I-antisauvagine-30 ((125)I-aSVG). The hCRF(...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید